1
|
Yang F, Dai L, Shi K, Liu Q, Pan M, Mo D, Deng H, Yuan L, Lu Y, Pan L, Yang T, Qian Z. A facile boronophenylalanine modified polydopamine dual drug-loaded nanoparticles for enhanced anti-tumor immune response in hepatocellular carcinoma comprehensive treatment. Biomaterials 2024; 305:122435. [PMID: 38150771 DOI: 10.1016/j.biomaterials.2023.122435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 11/28/2023] [Accepted: 12/16/2023] [Indexed: 12/29/2023]
Abstract
Hepatocellular carcinoma (HCC) has an insidious onset and high malignancy. Most patients have progressed to intermediate and advanced stages by the time of diagnosis, and the long-term efficacy of traditional treatments is not satisfactory. Immunotherapy has shown great promise in the treatment of HCC in recent years; however, the low immunogenicity and severe immunosuppressive tumor microenvironment result in a low response rate to immunotherapy in HCC patients. Therefore, it is of great significance to improve the immunogenicity of HCC and thus enhance its sensitivity to immunotherapy. Here, we prepared the boronophenylalanine-modified dual drug-loaded polydopamine nanoparticles by a facile method. This system used boronophenylalanine-modified polydopamine nanoparticles as a delivery vehicle and photothermal material for the chemotherapeutic drug doxorubicin and the immune agonist CpG oligodeoxynucleotides (CpG-ODN), with both active targeting and lysosomal escape functions. The cancer cells are rapidly killed by photothermal treatment, and then chemotherapy is used to further kill cancer cells that are inadequately treated by photothermal treatment. The combination of photothermal-chemotherapy synergistically induces the release of relevant antigens from tumor cells, thus initiating anti-tumor immunity; and then cooperates with CpG-ODN to trigger a powerful anti-tumor immune memory effect, potently and durably inhibiting HCC recurrence.
Collapse
Affiliation(s)
- Fan Yang
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China; Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Liqun Dai
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Kun Shi
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Qingya Liu
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Meng Pan
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Dong Mo
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Hanzhi Deng
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Liping Yuan
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Yi Lu
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Lili Pan
- Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
| | - Tingyu Yang
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Zhiyong Qian
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
| |
Collapse
|
2
|
Wang M, Hu D, Yang Y, Shi K, Li J, Liu Q, Li Y, Li R, Pan M, Mo D, Chen W, Li X, Qian Z. Enhanced Chemo-Immunotherapy Strategy Utilizing Injectable Thermosensitive Hydrogel for The Treatment of Diffuse Peritoneal Metastasis in Advanced Colorectal Cancer. Adv Sci (Weinh) 2023; 10:e2303819. [PMID: 37875399 PMCID: PMC10724414 DOI: 10.1002/advs.202303819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/11/2023] [Revised: 09/17/2023] [Indexed: 10/26/2023]
Abstract
Patients with colorectal cancer (CRC) and diffuse peritoneal metastasis (PM) are not eligible for surgical intervention. Thus, palliative treatment remains the standard of care in clinical practice. Systemic chemotherapy fails to cause drug accumulation at the lesion sites, while intraperitoneal chemotherapy (IPC) is limited by high clearance rates and associated complications. Given the poor prognosis, a customized OxP/R848@PLEL hydrogel delivery system has been devised to improve the clinical benefit of advanced CRC with diffuse PM. This system is distinguished by its simplicity, security, and efficiency. Specifically, the PLEL hydrogel exhibits excellent injectability and thermosensitivity, enabling the formation of drug depots within the abdominal cavity, rendering it an optimal carrier for IPC. Oxaliplatin (OxP), a first-line drug for advanced CRC, is cytotoxic and enhances the immunogenicity of tumors by inducing immunogenic cell death. Furthermore, OxP and resiquimod (R848) synergistically enhance the maturation of dendritic cells, promote the expansion of cytotoxic T lymphocytes, and induce the formation of central memory T cells. Moreover, R848 domesticates macrophages to an anti-tumor phenotype. OxP/R848@PLEL effectively eradicates peritoneal metastases, completely inhibits ascites production, and significantly prolongs mice lifespan. As such, it provides a promising approach to managing diffuse PM in patients with CRC without surgical indications.
Collapse
Affiliation(s)
- Meng Wang
- Department of BiotherapyCancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengdu610041China
| | - DanRong Hu
- Rehabilitation Medicine Center and Institute of Rehabilitation MedicineKey Laboratory of Rehabilitation Medicine in Sichuan ProvinceWest China HospitalSichuan UniversityChengdu610041China
| | - Yun Yang
- Department of BiotherapyCancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengdu610041China
| | - Kun Shi
- Department of BiotherapyCancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengdu610041China
| | - JiaNan Li
- Department of BiotherapyCancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengdu610041China
| | - QingYa Liu
- Department of BiotherapyCancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengdu610041China
| | - YiCong Li
- Department of BiotherapyCancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengdu610041China
| | - Ran Li
- Rehabilitation Medicine Center and Institute of Rehabilitation MedicineKey Laboratory of Rehabilitation Medicine in Sichuan ProvinceWest China HospitalSichuan UniversityChengdu610041China
| | - Meng Pan
- Department of BiotherapyCancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengdu610041China
| | - Dong Mo
- Department of BiotherapyCancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengdu610041China
| | - Wen Chen
- Department of BiotherapyCancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengdu610041China
| | - XiCheng Li
- Department of BiotherapyCancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengdu610041China
| | - ZhiYong Qian
- Department of BiotherapyCancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengdu610041China
| |
Collapse
|
3
|
Wan S, Zhang TT, Chen T, Zhang D, Mo D, Xu J, Tian HM, Ren Y. [Primary pigmented nodular adrenal disease: a report of three cases]. Zhonghua Nei Ke Za Zhi 2022; 61:944-947. [PMID: 35922222 DOI: 10.3760/cma.j.cn112138-20211031-00760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Affiliation(s)
- S Wan
- Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - T T Zhang
- Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - T Chen
- Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - D Zhang
- Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - D Mo
- Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - J Xu
- Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - H M Tian
- Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - Y Ren
- Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital, Sichuan University, Chengdu 610041, China
| |
Collapse
|
4
|
Caporali R, Aletaha D, Sanmartí R, Takeuchi T, Mo D, Haladyj E, Zaremba-Pechmann L, Taylor PC. POS0701 LONG-TERM EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE HAD INADEQUATE RESPONSE TO csDMARDs: RESULTS FROM RA-BEYOND UP TO 7 YEARS OF TREATMENT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundBaricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, has demonstrated efficacy in patients (pts) with rheumatoid arthritis (RA) for up to 3 years (yrs) in a long-term extension (LTE) study RA-BEYOND.1ObjectivesDisclose efficacy of BARI in csDMARD-IR pts in the completed LTE study (up to 7 yrs).MethodsIn RA-BUILD, csDMARD-IR pts were randomized 1:1:1 to BARI 4 mg, 2 mg, or placebo (PBO). Completers to week (wk) 24 could enter the LTE and received BARI 4 or 2 mg. In RA-BEAM, MTX-IR pts were randomized 1:1:1 to BARI 4 mg, adalimumab (ADA) 40 mg, or PBO. Completers to wk 52 received BARI 4 mg in the LTE. Pts with no response could be rescued after wk 16 in both studies. Data were analysed by treatment assigned at baseline in originating studies as observed up to time of stepdown (if applicable), study discontinuation or completion, whichever occurred earlier. Efficacy response rates (RR) were assessed as proportions of pts with observed data up to yr 7 (wk 364) for low-disease activity (LDA) (SDAI ≤ 11, DAS28-hsCRP ≤ 3.2, CDAI ≤ 10), remission (REM) (SDAI ≤ 3.3, DAS28-hsCRP < 2.6, CDAI ≤ 2.8, Boolean), and physical function (HAQ-DI ≤ 0.5). No formal statistical comparisons were conducted.ResultsApproximately 56%/25% of pts in BARI 4 mg, 80%/31% in BARI 2 mg, and 60%/25% in PBO from RA-BUILD remained active at yr 3/7; 59%/17% of pts in ADA, 54%/16% in BARI 4 mg, and 67%/14% in PBO from RA-BEAM remained active at year 3/7. SDAI and CDAI had comparable RR for LDA and REM (Table 1). DAS-28CRP LDA RR were similar to SDAI and CDAI, while REM RR were about twice those of SDAI and CDAI (Table 1). HAQ-DI ≤ 0.5 RR was achieved by 25-30% of BARI-treated pts from both trials and maintained to the end of LTE.Table 1.Efficacy outcomes in RA-BEYONDTimeaN/n (%)LDAREMHAQ-DI ≤0.5SDAICDAIDAS-28 CRPSDAICDAIDAS-28 CRPBooleanRA-BEYOND entryBARI 2 mg (BUILD)197/109197/103200/108197/38 (19.3)197/35 (17.8)200/72 (36.0)200/29 (14.5)200/50 (25.0)(55.3)(52.3)(54.0)BARI 4 mg (BUILD)188/113191/116189/112188/33191/35 (18.3)189/75 (39.7)189/26 (13.8)193/44 (22.8)(60.1)(60.7)(59.3)(17.6)BARI 4 mg (BEAM)412/288414/290412/280412/112414/108412/199412/78 (18.9)414/133 (27.3)(69.9)(70.0)(68.0)(27.2)(26.1)(48.3)Yr 3BARI 2 mg (BUILD)156/120158/116156/112156/41 (26.3)158/44 (27.8)156/81 (51.9)156/34 (21.8)159/38 (23.9)(76.9)(73.4)(71.8)BARI 4 mg (BUILD)107/76107/76107/74107/24107/26 (24.3)107/56 (52.3)107/17 (15.9)108/26 (24.1)(71.0)(71.0)(69.2)(22.4)BARI 4 mg (BEAM)222/166224/166222/164222/72224/71 (31.7)222/119222/48224/54 (24.1)(74.8)(74.1)(73.9)(32.4)(53.6)(21.6)Yr 7BARI 2 mg (BUILD)61/5061/4961/5161/17 (27.9)61/18 (29.5)61/40 (65.6)61/12 (19.7)62/16 (25.8)(82.0)(80.3)(83.6)BARI 4 mg (BUILD)45/3748/3745/3445/13 (28.9)48/16 (33.3)45/25 (55.6)45/8 (17.8)48/14 (29.2)(82.2)(77.1)(75.6)BARI 4 mg (BEAM)60/5364/5760/53 (88.3)60/18 (30.0)64/22 (34.4)60/38 (63.3)60/13 (21.7)64/14 (21.9)(88.3)(89.1)N: Number of pts with observed data; n: Number of pts with response. aTime from randomization in originating studies. Entry to RA-BEYOND=wk 24 and wk 52; Yr 3=wk 156 and wk 160; and Yr 7=wk 360 and wk 364 of RA-BUILD and RA-BEAM, respectively.ConclusionIn observed data, BARI demonstrated maintained efficacy in treatment and maintenance of physical function of a csDMARDs-IR RA pt population up to 7 yrs.References[1]Smolen JS, et al. Rheumatology (Oxford). 2021; 60(5):2256-66.Disclosure of InterestsRoberto Caporali Speakers bureau: Abbvie, Amgen, BMS, Celltrion, Eli Lilly and Company, Galapagos, Pfizer, Fresenius-Kabi, MSD, UCB, Roche,Janssen, Novartis, Sandoz, Consultant of: Abbvie, Amgen, BMS, Celltrion, Eli Lilly and Company, Galapagos, Pfizer, MSD, UCB, Janssen, Novartis, Sandoz, Daniel Aletaha Speakers bureau: Abbvie, Amgen, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Grant/research support from: Abbvie, Amgen, Eli Lilly and Company, Novartis, Roche, SoBi, Sanofi, Raimón Sanmartí Speakers bureau: Eli Lilly and Company, Grant/research support from: Eli Lilly and Company, Tsutomu Takeuchi Speakers bureau: AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co, Ltd. Daiichi Sankyo Co., Ltd. Eisai Co., Ltd. Eli Lilly Japan K.K.; Gilead Sciences, Inc. Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Co.; Novartis Pharma Co.; Pfizer Japan Inc.; Sanofi K.K.; UCB Japan Co., Ltd., Consultant of: AbbVie Japan GK, Astellas Pharma, Inc.; Chugai Pharmaceutical Co, Ltd.; Eli Lilly Japan K.K.; Eisai Co., Ltd.; Gilead Sciences, Inc.; Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Corp., Pfizer Japan Inc., Grant/research support from: AbbVie Japan GK, Asahikasei Pharma Corp., Chugai Pharmaceutical Co, Ltd., DNA Chip Research Inc.; Eisai Co., Ltd., Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Corp., UCB Japan Co., Ltd., Daojun Mo Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Ewa Haladyj Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Liliana Zaremba-Pechmann: None declared, Peter C. Taylor Consultant of: AbbVie, Biogen, Eli Lilly and Company, Fresenius, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Inc, Roche, and Sanofi, Grant/research support from: Celgene, and Galapagos
Collapse
|
5
|
Caporali R, Aletaha D, Sanmartí R, Takeuchi T, Mo D, Haladyj E, Zaremba-Pechmann L, Taylor PC. POS0682 LONG-TERM EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO bDMARDs: RESULTS FROM RA-BEYOND FOLLOWING 6.9 YEARS OF TREATMENT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundBaricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, is approved for treatment of adults with moderately-to-severely active rheumatoid arthritis (RA). BARI demonstrated efficacy in patients (pts) with RA who have inadequate response to biologic disease-modifying antirheumatic drugs (bDMARD-IR) in a 24-week (wk) phase 3 study, RA-BEACON.1 BARI efficacy was evaluated up to 3 years (yrs) of treatment in a long-term extension (LTE) study, RA-BEYOND.2ObjectivesDisclose long-term efficacy of BARI 4 mg and 2 mg in bDMARD-IR pts in the completed study RA-BEYOND.MethodsIn RA-BEACON, pts were randomized 1:1:1 to BARI 4 mg, 2 mg, or PBO; pts with no response could be rescued after wk 16. Completers to wk 24 could enter with BARI 4 or 2mg RA-BEYOND for up to 360 wks (6.9 yrs). LTE data were analysed by treatment assigned at baseline in RA-BEACON as observed up to time of stepdown (if applicable), study discontinuation, or study completion, whichever occurred earlier. Efficacy response rates (RR) were assessed as proportions of pts with observed data up to wk 360 for low-disease activity (LDA) (SDAI ≤ 11, DAS28-hsCRP ≤ 3.2, CDAI ≤ 10), remission (REM) (SDAI ≤ 3.3, DAS28-hsCRP < 2.6, CDAI ≤ 2.8, Boolean), and physical functioning (HAQ-DI ≤ 0.5). No formal statistical comparisons were conducted.Results156, 152, and 140 pts entered the LTE (4 mg, 2 mg, and PBO, respectively). Pts in BARI 4 and 2 mg arms had higher LDA and REM RR vs PBO at LTE entry (wk 24) (Table 1). PBO-treated pts achieved comparable RR to pts in the BARI 4 mg arm by wk 48 (24 wks after switch to BARI 4 mg) and up to wk 360. Of pts enrolled to RA-BEYOND, approx. 50% in BARI 4 mg, 65% in 2 mg and 61% in PBO remained active at wk 156; 17%, 26% and 26% at wk 360, respectively. SDAI LDA RR were 47%/70% and 61%/74% for pts treated with BARI 4 mg and 2 mg, at wk 156 (yr 3)/ 360 (yr 6.9), respectively; SDAI REM RR were 15%/26% and 26%/26% for BARI 4 mg and 2 mg, at wk 156/360, respectively (Table 1). SDAI and CDAI had comparable RR. DAS-28CRP LDA RR were similar to SDAI and CDAI, while REM RR were about twice those of SDAI and CDAI. HAQ-DI ≤ 0.5 RR was 15%/26% (BARI 4 mg), 21%/15% (BARI 2mg), and 9%/3% (PBO) at 3/6.9 yrs.Table 1.Efficacy outcomes in RA-BEYONDTimeaN/n (%)LDAREMSDAICDAIDAS-28 CRPSDAICDAIDAS-28 CRPBooleanHAQ-DI ≤0.5Wk 24PBOb135/31 (23.0)138/32 (23.2)135/31 (23.0)135/6 (4.4)138/8 (5.8)135/14 (10.4)135/3139/6 (4.3)(2.2)BARI 2 mg148/42 (28.4)152/43 (28.3)148/38 (25.7)148/10 (6.8)152/10 (6.6)148/22 (14.9)148/9152/17 (11.2)(6.1)BARI 4 mg150/57 (38.0)156/60 (38.5)150/60 (40.0)150/14 (9.3)156/17 (10.9)150/37 (24.7)150/11 (7.3)156/17 (10.9)Wk 48PBO128/59 (46.1)129/58 (45.0)128/58 (45.3)128/14 (10.9)129/15 (11.6)128/31 (24.2)128/5130/6 (4.6)(3.9)BARI 2 mg139/54 (38.8)140/56 (40.0)139/53 (38.1)139/13 (9.4)140/14 (10.0)139/30 (21.6)139/11 (7.9)140/16 (11.4)BARI 4 mg147/70 (47.6)149/71 (47.7)147/68 (46.3)147/22 (15.0)149/19 (12.8)147/49 (33.3)147/14 (9.5)149/19 (12.8)Wk 156PBO84/47 (56.0)85/47 (55.3)84/45 (53.6)84/15 (17.9)85/14 (16.5)84/33 (39.3)84/985/8 (9.4)(10.7)BARI 2 mg98/60 (61.2)99/60 (60.6)98/58 (59.2)98/25 (25.5)99/27 (27.3)98/43 (43.9)98/13 (13.3)99/21 (21.2)BARI 4 mg76/36 (47.4)78/35 (44.9)76/37 (48.7)76/11 (14.5)78/13 (16.7)76/25 (32.9)76/978/12 (15.4)(11.8)Wk 360PBO33/26 (78.8)35/25 (71.4)34/27 (79.4)33/8 (24.2)35/9 (25.7)34/17 (50.0)34/636/1 (2.8)(17.6)BARI 2 mg38/28 (73.7)38/28 (73.7)38/27 (71.1)38/10 (26.3)38/8 (21.1)38/20 (52.6)38/539/6 (15.4)(13.2)BARI 4 mg27/19 (70.4)27/20 (74.1)27/20 (74.1)27/7 (25.9)27/7 (25.9)27/15 (55.6)27/427/7 (25.9)(14.8)N: Number of pts with observed data; n: Number of pts with response. aNumber of wks from randomisation. bTreatment groups as assigned at randomisation.ConclusionIn observed data, BARI maintained efficacy and normative physical function bDMARD-IR population up to 6.9 yrs (360 wks).References[1]Genovese MC et al. N Engl J Med. 2016; 374:1243-52[2]Wells AF et al. Rheumatol Ther. 2021; 8:987–1001Disclosure of InterestsRoberto Caporali Speakers bureau: Abbvie, Amgen, BMS, Celltrion, Eli Lilly and Company, Galapagos, Pfizer, Fresenius-Kabi, MSD, UCB, Roche,Janssen, Novartis, Sandoz, Consultant of: Abbvie, Amgen, BMS, Celltrion, Eli Lilly and Company, Galapagos, Pfizer, MSD, UCB, Janssen, Novartis, Sandoz, Daniel Aletaha Speakers bureau: Abbvie, Amgen, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Grant/research support from: Abbvie, Amgen, Eli Lilly and Company, Novartis, Roche, SoBi, Sanofi, Raimón Sanmartí Speakers bureau: Eli Lilly and Company, Grant/research support from: Eli Lilly and Company, Tsutomu Takeuchi Speakers bureau: AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co, Ltd. Daiichi Sankyo Co., Ltd. Eisai Co., Ltd. Eli Lilly Japan K.K.; Gilead Sciences, Inc. Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Co.; Novartis Pharma Co.; Pfizer Japan Inc.; Sanofi K.K.; UCB Japan Co., Ltd., Consultant of: AbbVie Japan GK, Astellas Pharma, Inc.; Chugai Pharmaceutical Co, Ltd.; Eli Lilly Japan K.K.; Eisai Co., Ltd.; Gilead Sciences, Inc.; Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Corp., Pfizer Japan Inc., Grant/research support from: AbbVie Japan GK, Asahikasei Pharma Corp., Chugai Pharmaceutical Co, Ltd., DNA Chip Research Inc.; Eisai Co., Ltd., Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Corp., UCB Japan Co., Ltd., Daojun Mo Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Ewa Haladyj Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Liliana Zaremba-Pechmann: None declared, Peter C. Taylor Consultant of: AbbVie, Biogen, Eli Lilly and Company, Fresenius, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Inc, Roche, and Sanofi, Grant/research support from: Celgene and Galapagos
Collapse
|
6
|
Alemanno F, An Q, Azzarello P, Barbato FCT, Bernardini P, Bi XJ, Cai MS, Catanzani E, Chang J, Chen DY, Chen JL, Chen ZF, Cui MY, Cui TS, Cui YX, Dai HT, D'Amone A, De Benedittis A, De Mitri I, de Palma F, Deliyergiyev M, Di Santo M, Dong TK, Dong ZX, Donvito G, Droz D, Duan JL, Duan KK, D'Urso D, Fan RR, Fan YZ, Fang K, Fang F, Feng CQ, Feng L, Fusco P, Gao M, Gargano F, Gong K, Gong YZ, Guo DY, Guo JH, Guo XL, Han SX, Hu YM, Huang GS, Huang XY, Huang YY, Ionica M, Jiang W, Kong J, Kotenko A, Kyratzis D, Lei SJ, Li S, Li WL, Li X, Li XQ, Liang YM, Liu CM, Liu H, Liu J, Liu SB, Liu WQ, Liu Y, Loparco F, Luo CN, Ma M, Ma PX, Ma T, Ma XY, Marsella G, Mazziotta MN, Mo D, Niu XY, Pan X, Parenti A, Peng WX, Peng XY, Perrina C, Qiao R, Rao JN, Ruina A, Salinas MM, Shang GZ, Shen WH, Shen ZQ, Shen ZT, Silveri L, Song JX, Stolpovskiy M, Su H, Su M, Sun ZY, Surdo A, Teng XJ, Tykhonov A, Wang H, Wang JZ, Wang LG, Wang S, Wang XL, Wang Y, Wang YF, Wang YZ, Wang ZM, Wei DM, Wei JJ, Wei YF, Wen SC, Wu D, Wu J, Wu LB, Wu SS, Wu X, Xia ZQ, Xu HT, Xu ZH, Xu ZL, Xu ZZ, Xue GF, Yang HB, Yang P, Yang YQ, Yao HJ, Yu YH, Yuan GW, Yuan Q, Yue C, Zang JJ, Zhang F, Zhang SX, Zhang WZ, Zhang Y, Zhang YJ, Zhang YL, Zhang YP, Zhang YQ, Zhang Z, Zhang ZY, Zhao C, Zhao HY, Zhao XF, Zhou CY, Zhu Y. Measurement of the Cosmic Ray Helium Energy Spectrum from 70 GeV to 80 TeV with the DAMPE Space Mission. Phys Rev Lett 2021; 126:201102. [PMID: 34110215 DOI: 10.1103/physrevlett.126.201102] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 03/25/2021] [Accepted: 04/06/2021] [Indexed: 06/12/2023]
Abstract
The measurement of the energy spectrum of cosmic ray helium nuclei from 70 GeV to 80 TeV using 4.5 years of data recorded by the Dark Matter Particle Explorer (DAMPE) is reported in this work. A hardening of the spectrum is observed at an energy of about 1.3 TeV, similar to previous observations. In addition, a spectral softening at about 34 TeV is revealed for the first time with large statistics and well controlled systematic uncertainties, with an overall significance of 4.3σ. The DAMPE spectral measurements of both cosmic protons and helium nuclei suggest a particle charge dependent softening energy, although with current uncertainties a dependence on the number of nucleons cannot be ruled out.
Collapse
Affiliation(s)
- F Alemanno
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - Q An
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - P Azzarello
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - F C T Barbato
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - P Bernardini
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - X J Bi
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
| | - M S Cai
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - E Catanzani
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Perugia, I-06123 Perugia, Italy
| | - J Chang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - D Y Chen
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - J L Chen
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Z F Chen
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - M Y Cui
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - T S Cui
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Y X Cui
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - H T Dai
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - A D'Amone
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - A De Benedittis
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - I De Mitri
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - F de Palma
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - M Deliyergiyev
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - M Di Santo
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - T K Dong
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z X Dong
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - G Donvito
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Bari, I-70125 Bari, Italy
| | - D Droz
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - J L Duan
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - K K Duan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - D D'Urso
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Perugia, I-06123 Perugia, Italy
| | - R R Fan
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - Y Z Fan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - K Fang
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - F Fang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - C Q Feng
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - L Feng
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - P Fusco
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Bari, I-70125 Bari, Italy
- Dipartimento di Fisica "M. Merlin" dell'Università e del Politecnico di Bari, I-70126 Bari, Italy
| | - M Gao
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - F Gargano
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Bari, I-70125 Bari, Italy
| | - K Gong
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - Y Z Gong
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - D Y Guo
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J H Guo
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - X L Guo
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - S X Han
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Y M Hu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - G S Huang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - X Y Huang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - Y Y Huang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - M Ionica
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Perugia, I-06123 Perugia, Italy
| | - W Jiang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - J Kong
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - A Kotenko
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - D Kyratzis
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - S J Lei
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - S Li
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - W L Li
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - X Li
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - X Q Li
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Y M Liang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - C M Liu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - H Liu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - J Liu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - S B Liu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - W Q Liu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y Liu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - F Loparco
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Bari, I-70125 Bari, Italy
- Dipartimento di Fisica "M. Merlin" dell'Università e del Politecnico di Bari, I-70126 Bari, Italy
| | - C N Luo
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - M Ma
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - P X Ma
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - T Ma
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - X Y Ma
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - G Marsella
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - M N Mazziotta
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Bari, I-70125 Bari, Italy
| | - D Mo
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - X Y Niu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - X Pan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - A Parenti
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - W X Peng
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - X Y Peng
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - C Perrina
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - R Qiao
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J N Rao
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - A Ruina
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - M M Salinas
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - G Z Shang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - W H Shen
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Z Q Shen
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z T Shen
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - L Silveri
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - J X Song
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - M Stolpovskiy
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - H Su
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - M Su
- Department of Physics and Laboratory for Space Research, the University of Hong Kong, Pok Fu Lam, Hong Kong SAR 999077, China
| | - Z Y Sun
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - A Surdo
- Istituto Nazionale di Fisica Nucleare (INFN)-Sezione di Lecce, I-73100 Lecce, Italy
| | - X J Teng
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - A Tykhonov
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - H Wang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - J Z Wang
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - L G Wang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - S Wang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - X L Wang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y Wang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y F Wang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y Z Wang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z M Wang
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L'Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)-Laboratori Nazionali del Gran Sasso, I-67100 Assergi, L'Aquila, Italy
| | - D M Wei
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - J J Wei
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Y F Wei
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - S C Wen
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - D Wu
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J Wu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - L B Wu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - S S Wu
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - X Wu
- Department of Nuclear and Particle Physics, University of Geneva, CH-1211 Geneva, Switzerland
| | - Z Q Xia
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - H T Xu
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Z H Xu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - Z L Xu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z Z Xu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - G F Xue
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - H B Yang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - P Yang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y Q Yang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - H J Yao
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y H Yu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - G W Yuan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - Q Yuan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - C Yue
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - J J Zang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - F Zhang
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - S X Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - W Z Zhang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Y Zhang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Y J Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y L Zhang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y P Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y Q Zhang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z Zhang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210023, China
| | - Z Y Zhang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - C Zhao
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - H Y Zhao
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - X F Zhao
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - C Y Zhou
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| | - Y Zhu
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian district, Beijing 100190, China
| |
Collapse
|
7
|
Liu G, Wang L, Liu J, Lu L, Mo D, Li K, Yang X, Zeng R, Zhang J, Liu P, Cai K. Engineering of a Core-Shell Nanoplatform to Overcome Multidrug Resistance via ATP Deprivation. Adv Healthc Mater 2020; 9:e2000432. [PMID: 32945146 DOI: 10.1002/adhm.202000432] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Revised: 06/14/2020] [Indexed: 12/22/2022]
Abstract
Inhibiting the function of P-glycoprotein (P-gp) transporter, which causes drug efflux through adenosine triphosphate (ATP)-dependent manner, has become an effective strategy to conquer multidrug resistance (MDR) of cancer cells. However, there remains challenges for effective co-delivery, sequential release of P-gp modulator and chemotherapeutic agent. In this work, a novel type of core-shell nanoparticle is reported. It can independently encapsulate a high amount (about 683 µg mg-1 ) of chemotherapeutic agent doxorubicin (DOX) in the mesoporous polydopamine (MPDA) core and glucose oxidase (GOx) in the zeolite imidazolate frameworks-8 (ZIF-8) shell, namely MPDA@ZIF-8/DOX+GOx. The fast release of GOx triggered by acid-sensitive degradation of the ZIF-8 shell consumes glucose to starve cancer cells for ATP deprivation and effective suppress ATP-dependent drug efflux in advance, and then effectively facilitates the accumulation of DOX in MCF-7/ADR cancer cells. Experiments in vitro and in vivo demonstrate that the fabricated nanosystem can dramatically improve anticancer effects for MDR through sequential release property and exhibit excellent biocompatibility. Overall, this work reveals new insights in the use of GOx for MDR treatment.
Collapse
Affiliation(s)
- Genhua Liu
- Key Laboratory of Biorheological Science and Technology of Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
| | - Liucan Wang
- Key Laboratory of Biorheological Science and Technology of Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
| | - Junjie Liu
- Key Laboratory of Biorheological Science and Technology of Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
| | - Lu Lu
- Key Laboratory of Biorheological Science and Technology of Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
| | - Dong Mo
- Key Laboratory of Biorheological Science and Technology of Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
| | - Ke Li
- Key Laboratory of Biorheological Science and Technology of Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
| | - Xin Yang
- Key Laboratory of Biorheological Science and Technology of Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
| | - Rui Zeng
- Key Laboratory of Biorheological Science and Technology of Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
| | - Jixi Zhang
- Key Laboratory of Biorheological Science and Technology of Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
| | - Peng Liu
- Key Laboratory of Biorheological Science and Technology of Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
- Chongqing Key Laboratory of Soft‐Matter Material Chemistry and Function Manufacturing Chongqing 400044 China
| | - Kaiyong Cai
- Key Laboratory of Biorheological Science and Technology of Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China
- Chongqing Key Laboratory of Soft‐Matter Material Chemistry and Function Manufacturing Chongqing 400044 China
| |
Collapse
|
8
|
Genovese MC, Smolen JS, Takeuchi T, Burmester GR, Deberdt W, Schlichting D, Song H, Mo D, Walls C, Winthrop K. FRI0123 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 8.4 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1723] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1 and 2, approved for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults.Objectives:Here we update the drug’s safety profile with data up to 8.4 years of treatment.Methods:Long-term safety of bari was assessed from 9 completed randomized trials (5 Ph3, 3 Ph2, 1 Ph 1b) and 1 ongoing long-term extension (LTE) study. Incidence rates (IR) per 100 patient-years (PY) were calculated for all patients with RA treated with ≥1 dose of bari through 1-Sep-2019 (All-Bari-RA analysis set). IRs for deep vein thrombosis (DVT), pulmonary embolism (PE), and DVT and/or PE (DVT/PE) were also calculated for groups of patients while receiving bari 2mg or bari 4mg within All-Bari-RA. Major adverse cardiovascular events (MACE) were adjudicated in 5 phase 3 studies and the LTE.Results:3770 pts received bari for 13,148 PY, with a median and maximum exposure of 4.2 and 8.4 years, respectively. Overall IRs per 100 PY were: for any treatment-emergent adverse event (AE)(25.8); serious AE (including death)(7.2); temporary interruption due to AE (9.5); permanent discontinuation due to AE (4.8); death (0.52); serious infection (2.7); opportunistic infection (0.44) (excluding tuberculosis [TB], including multidermatomal herpes zoster [HZ]); TB (0.15); HZ (3.0); MACE (0.50); DVT (0.31); PE (0.24); DVT/PE (0.45); malignancies excluding non-melanoma skin cancer (NMSC) (0.90); NMSC (0.33); lymphoma (0.06); and gastrointestinal perforation (0.04). Incidence rates (IR)[95% confidence intervals] for patients while receiving bari 2mg (N=1077) and bari 4mg (N=3400) were DVT 2mg (0.38) [0.18, 0.73] and 4mg (0.30) [0.21, 0.43]; PE 2mg (0.26) [0.09, 0.56] and 4mg (0.25) [0.16, 0.36]; and DVT/PE 2mg (0.47) [0.23, 0.84] and 4mg (0.46) [0.34, 0.61]. IRs for death tended to increase in later time intervals (beyond 192 weeks). No particular cause of death contributed to this increase. For all other safety topics of interest, across 48-week treatment intervals, IRs remained stable over time. Across safety topics, IRs were consistent with previous analyses1,2.Conclusion:In this update with 3,021 additional PY of exposure, bari maintained a safety profile similar to that previously reported,1,2with no increase of IRs across safety topics through exposures up to 8.4 years.References:[1]Smolen JS et al. J Rheumatol. 2019 Jan;46(1):7-18[2]Genovese MC et al. Ann Rheum Dis. 2019 78(supp. 2):A308Table.n/NARIRTreatment emergent AE3391/377025.8Serious AE (including death)940/37707.2Temporary d/c due to AE1241/36479.5Permanent d/c due to AE644/37704.8Death69/37700.52Serious infection344/37702.7Opportunistic infection (excluding tuberculosis, including multidermatomal herpes zoster)59/37700.44Herpes zoster384/37703.0Tuberculosis20/37700.15Major adverse cardiovascular events*63/32510.50DVT41/37700.31PE32/37700.24DVT and/or PE60/37700.45Malignancies excluding NMSC120/37700.90NMSC44/37700.33Lymphoma8/37700.06Gastrointestinal perforation6/37700.04*studies with positive adjudication. AE=adverse event; D/C= discontinuation; DVT=deep vein thrombosis; IR=incidence rate; NAR=number of patients at risk; NMSC=non-melanoma skin cancer; PE=pulmonary embolismDisclosure of Interests:Mark C. Genovese Grant/research support from: Abbvie, Eli Lilly and Company, EMD Merck Serono, Galapagos, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, Pfizer Inc., RPharm, Sanofi Genzyme, Consultant of: Abbvie, Eli Lilly and Company, EMD Merck Serono, Genentech/Roche, Gilead Sciences, Inc., GSK, Novartis, RPharm, Sanofi Genzyme, Josef S. Smolen Grant/research support from: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Consultant of: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Tsutomu Takeuchi Grant/research support from: Eisai Co., Ltd, Astellas Pharma Inc., AbbVie GK, Asahi Kasei Pharma Corporation, Nippon Kayaku Co., Ltd, Takeda Pharmaceutical Company Ltd, UCB Pharma, Shionogi & Co., Ltd., Mitsubishi-Tanabe Pharma Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co. Ltd., Consultant of: Chugai Pharmaceutical Co Ltd, Astellas Pharma Inc., Eli Lilly Japan KK, Speakers bureau: AbbVie GK, Eisai Co., Ltd, Mitsubishi-Tanabe Pharma Corporation, Chugai Pharmaceutical Co Ltd, Bristol-Myers Squibb Company, AYUMI Pharmaceutical Corp., Eisai Co., Ltd, Daiichi Sankyo Co., Ltd., Gilead Sciences, Inc., Novartis Pharma K.K., Pfizer Japan Inc., Sanofi K.K., Dainippon Sumitomo Co., Ltd., Gerd Rüdiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Walter Deberdt Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Douglas Schlichting Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Hongsuk Song Employee of: Syneos Health under contract to Eli Lilly and Company, Daojun Mo Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Chad Walls Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Kevin Winthrop Grant/research support from: Bristol-Myers Squibb, Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Galapagos, Gilead, GSK, Pfizer Inc, Roche, UCB
Collapse
|
9
|
An Q, Asfandiyarov R, Azzarello P, Bernardini P, Bi XJ, Cai MS, Chang J, Chen DY, Chen HF, Chen JL, Chen W, Cui MY, Cui TS, Dai HT, D’Amone A, De Benedittis A, De Mitri I, Di Santo M, Ding M, Dong TK, Dong YF, Dong ZX, Donvito G, Droz D, Duan JL, Duan KK, D’Urso D, Fan RR, Fan YZ, Fang F, Feng CQ, Feng L, Fusco P, Gallo V, Gan FJ, Gao M, Gargano F, Gong K, Gong YZ, Guo DY, Guo JH, Guo XL, Han SX, Hu YM, Huang GS, Huang XY, Huang YY, Ionica M, Jiang W, Jin X, Kong J, Lei SJ, Li S, Li WL, Li X, Li XQ, Li Y, Liang YF, Liang YM, Liao NH, Liu CM, Liu H, Liu J, Liu SB, Liu WQ, Liu Y, Loparco F, Luo CN, Ma M, Ma PX, Ma SY, Ma T, Ma XY, Marsella G, Mazziotta MN, Mo D, Niu XY, Pan X, Peng WX, Peng XY, Qiao R, Rao JN, Salinas MM, Shang GZ, Shen WH, Shen ZQ, Shen ZT, Song JX, Su H, Su M, Sun ZY, Surdo A, Teng XJ, Tykhonov A, Vitillo S, Wang C, Wang H, Wang HY, Wang JZ, Wang LG, Wang Q, Wang S, Wang XH, Wang XL, Wang YF, Wang YP, Wang YZ, Wang ZM, Wei DM, Wei JJ, Wei YF, Wen SC, Wu D, Wu J, Wu LB, Wu SS, Wu X, Xi K, Xia ZQ, Xu HT, Xu ZH, Xu ZL, Xu ZZ, Xue GF, Yang HB, Yang P, Yang YQ, Yang ZL, Yao HJ, Yu YH, Yuan Q, Yue C, Zang JJ, Zhang F, Zhang JY, Zhang JZ, Zhang PF, Zhang SX, Zhang WZ, Zhang Y, Zhang YJ, Zhang YL, Zhang YP, Zhang YQ, Zhang Z, Zhang ZY, Zhao H, Zhao HY, Zhao XF, Zhou CY, Zhou Y, Zhu X, Zhu Y, Zimmer S. Measurement of the cosmic ray proton spectrum from 40 GeV to 100 TeV with the DAMPE satellite. Sci Adv 2019; 5:eaax3793. [PMID: 31799401 PMCID: PMC6868675 DOI: 10.1126/sciadv.aax3793] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Accepted: 09/03/2019] [Indexed: 05/23/2023]
Abstract
The precise measurement of the spectrum of protons, the most abundant component of the cosmic radiation, is necessary to understand the source and acceleration of cosmic rays in the Milky Way. This work reports the measurement of the cosmic ray proton fluxes with kinetic energies from 40 GeV to 100 TeV, with 2 1/2 years of data recorded by the DArk Matter Particle Explorer (DAMPE). This is the first time that an experiment directly measures the cosmic ray protons up to ~100 TeV with high statistics. The measured spectrum confirms the spectral hardening at ~300 GeV found by previous experiments and reveals a softening at ~13.6 TeV, with the spectral index changing from ~2.60 to ~2.85. Our result suggests the existence of a new spectral feature of cosmic rays at energies lower than the so-called knee and sheds new light on the origin of Galactic cosmic rays.
Collapse
Affiliation(s)
| | - Q. An
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - R. Asfandiyarov
- Department of Nuclear and Particle Physics, University of Geneva, Geneva CH-1211, Switzerland
| | - P. Azzarello
- Department of Nuclear and Particle Physics, University of Geneva, Geneva CH-1211, Switzerland
| | - P. Bernardini
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Lecce, I-73100 Lecce, Italy
| | - X. J. Bi
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
| | - M. S. Cai
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - J. Chang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - D. Y. Chen
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - H. F. Chen
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - J. L. Chen
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - W. Chen
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - M. Y. Cui
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - T. S. Cui
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - H. T. Dai
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - A. D’Amone
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Lecce, I-73100 Lecce, Italy
| | - A. De Benedittis
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Lecce, I-73100 Lecce, Italy
| | - I. De Mitri
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L’Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)–Laboratori Nazionali del Gran Sasso, Assergi, I-67100 L’Aquila, Italy
| | - M. Di Santo
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Lecce, I-73100 Lecce, Italy
| | - M. Ding
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - T. K. Dong
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - Y. F. Dong
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - Z. X. Dong
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - G. Donvito
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Bari, I-70125, Bari, Italy
| | - D. Droz
- Department of Nuclear and Particle Physics, University of Geneva, Geneva CH-1211, Switzerland
| | - J. L. Duan
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - K. K. Duan
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - D. D’Urso
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Perugia, I-06123 Perugia, Italy
| | - R. R. Fan
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - Y. Z. Fan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - F. Fang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - C. Q. Feng
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - L. Feng
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - P. Fusco
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Bari, I-70125, Bari, Italy
- Dipartimento di Fisica “M. Merlin” dell’Università e del Politecnico di Bari, I-70126 Bari, Italy
| | - V. Gallo
- Department of Nuclear and Particle Physics, University of Geneva, Geneva CH-1211, Switzerland
| | - F. J. Gan
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - M. Gao
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - F. Gargano
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Bari, I-70125, Bari, Italy
| | - K. Gong
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - Y. Z. Gong
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - D. Y. Guo
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J. H. Guo
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - X. L. Guo
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - S. X. Han
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - Y. M. Hu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - G. S. Huang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - X. Y. Huang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - Y. Y. Huang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - M. Ionica
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Perugia, I-06123 Perugia, Italy
| | - W. Jiang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - X. Jin
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - J. Kong
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - S. J. Lei
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - S. Li
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - W. L. Li
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - X. Li
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - X. Q. Li
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - Y. Li
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y. F. Liang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - Y. M. Liang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - N. H. Liao
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - C. M. Liu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - H. Liu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - J. Liu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - S. B. Liu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - W. Q. Liu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y. Liu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - F. Loparco
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Bari, I-70125, Bari, Italy
- Dipartimento di Fisica “M. Merlin” dell’Università e del Politecnico di Bari, I-70126 Bari, Italy
| | - C. N. Luo
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - M. Ma
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - P. X. Ma
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - S. Y. Ma
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - T. Ma
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - X. Y. Ma
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - G. Marsella
- Dipartimento di Matematica e Fisica E. De Giorgi, Università del Salento, I-73100 Lecce, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Lecce, I-73100 Lecce, Italy
| | - M. N. Mazziotta
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Bari, I-70125, Bari, Italy
| | - D. Mo
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - X. Y. Niu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - X. Pan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - W. X. Peng
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - X. Y. Peng
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - R. Qiao
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J. N. Rao
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - M. M. Salinas
- Department of Nuclear and Particle Physics, University of Geneva, Geneva CH-1211, Switzerland
| | - G. Z. Shang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - W. H. Shen
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - Z. Q. Shen
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - Z. T. Shen
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - J. X. Song
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - H. Su
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - M. Su
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- Department of Physics and Laboratory for Space Research, The University of Hong Kong, Pok Fu Lam, Hong Kong, China
| | - Z. Y. Sun
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - A. Surdo
- Istituto Nazionale di Fisica Nucleare (INFN)–Sezione di Lecce, I-73100 Lecce, Italy
| | - X. J. Teng
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - A. Tykhonov
- Department of Nuclear and Particle Physics, University of Geneva, Geneva CH-1211, Switzerland
| | - S. Vitillo
- Department of Nuclear and Particle Physics, University of Geneva, Geneva CH-1211, Switzerland
| | - C. Wang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - H. Wang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - H. Y. Wang
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J. Z. Wang
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - L. G. Wang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - Q. Wang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - S. Wang
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - X. H. Wang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - X. L. Wang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y. F. Wang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y. P. Wang
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - Y. Z. Wang
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - Z. M. Wang
- Gran Sasso Science Institute (GSSI), Via Iacobucci 2, I-67100 L’Aquila, Italy
- Istituto Nazionale di Fisica Nucleare (INFN)–Laboratori Nazionali del Gran Sasso, Assergi, I-67100 L’Aquila, Italy
| | - D. M. Wei
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - J. J. Wei
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - Y. F. Wei
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - S. C. Wen
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - D. Wu
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J. Wu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - L. B. Wu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - S. S. Wu
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - X. Wu
- Department of Nuclear and Particle Physics, University of Geneva, Geneva CH-1211, Switzerland
| | - K. Xi
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Z. Q. Xia
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - H. T. Xu
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - Z. H. Xu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - Z. L. Xu
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - Z. Z. Xu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - G. F. Xue
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - H. B. Yang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - P. Yang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y. Q. Yang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Z. L. Yang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - H. J. Yao
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y. H. Yu
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Q. Yuan
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
- School of Astronomy and Space Science, University of Science and Technology of China, Hefei 230026, China
| | - C. Yue
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - J. J. Zang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - F. Zhang
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J. Y. Zhang
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - J. Z. Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - P. F. Zhang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - S. X. Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - W. Z. Zhang
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - Y. Zhang
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - Y. J. Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y. L. Zhang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y. P. Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - Y. Q. Zhang
- University of Chinese Academy of Sciences, Yuquan Road 19A, Beijing 100049, China
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - Z. Zhang
- Key Laboratory of Dark Matter and Space Astronomy, Purple Mountain Observatory, Chinese Academy of Sciences, Nanjing 210033, China
| | - Z. Y. Zhang
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - H. Zhao
- Institute of High Energy Physics, Chinese Academy of Sciences, Yuquan Road 19B, Beijing 100049, China
| | - H. Y. Zhao
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - X. F. Zhao
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - C. Y. Zhou
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - Y. Zhou
- Institute of Modern Physics, Chinese Academy of Sciences, Nanchang Road 509, Lanzhou 730000, China
| | - X. Zhu
- State Key Laboratory of Particle Detection and Electronics, University of Science and Technology of China, Hefei 230026, China
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Y. Zhu
- National Space Science Center, Chinese Academy of Sciences, Nanertiao 1, Zhongguancun, Haidian District, Beijing 100190, China
| | - S. Zimmer
- Department of Nuclear and Particle Physics, University of Geneva, Geneva CH-1211, Switzerland
| |
Collapse
|
10
|
Abstract
First principle (FP) calculations were performed to systematically study the structural properties of ZrN, LaN and ThN with GGA correction. The ground state properties, wave velocities and Debye temperature of B1, P63/mmc, Pnma and B2 phase in ZrN, LaN and ThN were investigated and agree well with other theoretical and experimental results. More importantly, some novel phases are predicted in these materials, i.e. with the increasing pressure the phase transition sequence in ZrN and ThN is found to be B1 → P63/mmc → B2 phase, while in LaN, the sequence of B1 → Pnma → B2 is observed. Furthermore, our calculated elastic properties also confirm the prediction of phase transition under high pressure. These phase transitions arise from the optical phonon softening of B1 at around X, M and G points of Brillouin zone and P63/mmc (or Pnma) structure at around G, and H-K points.
Collapse
Affiliation(s)
- Y L Li
- School of Nuclear Science and Engineering, North China Electric Power University, Beijing 102206, People's Republic of China
| | | | | | | |
Collapse
|
11
|
Xing Y, Ding T, Wang Z, Wang L, Guan H, Tang J, Mo D, Zhang J. Temporally Controlled Photothermal/Photodynamic and Combined Therapy for Overcoming Multidrug Resistance of Cancer by Polydopamine Nanoclustered Micelles. ACS Appl Mater Interfaces 2019; 11:13945-13953. [PMID: 30907570 DOI: 10.1021/acsami.9b00472] [Citation(s) in RCA: 61] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Currently, the simple integration of multiple therapeutic agents within a single nanostructure for combating multidrug resistance (MDR) tumors yet remains a challenge. Herein, we report a photoresponsive nanocluster (NC) system prepared by installing polydopamine (PDA) nanoparticle clusters on the surface of d-α-tocopheryl poly(ethylene glycol) 1000 succinate (TPGS) (a drug efflux inhibitor) micelles solubilized with IR780 (a photosensitizer) to achieve a combined chemotherapy (CT)/photothermal therapy (PTT)/photodynamic therapy (PDT) for drug-resistant breast cancer. Mediated by the fluorescence resonance energy transfer and radical scavenging properties of PDA, NC shows prominently quenched fluorescence emission (∼78%) and inhibited singlet oxygen generation (∼67%) upon exposure to near-infrared (NIR) light (808 nm, 0.5 W cm-2), favoring a highly efficient PTT module. Meanwhile, the photothermal heat can also boost the release of doxorubicin hydrochloride whose intracellular accumulation can be greatly enhanced by TPGS. Interestingly, the first NIR irradiation and subsequent incubation (∼24 h) can induce the gradual relocation and disintegration of PDA nanoparticles, thereby leading to activated PDT therapy under the second irradiation. Upon the temporally controlled sequential application of PTT/PDT, the developed NC exhibited a great potential to treat MDR cancer both in vitro and in vivo. These findings suggest that complementary interactions among PTT/PDT/CT modalities can enhance the efficiency of the combined therapy for MDR tumor.
Collapse
Affiliation(s)
- Yuxin Xing
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering , Chongqing University , No. 174 Shazheng Road , Chongqing 400044 , China
| | - Tao Ding
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering , Chongqing University , No. 174 Shazheng Road , Chongqing 400044 , China
| | - Zhenqiang Wang
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering , Chongqing University , No. 174 Shazheng Road , Chongqing 400044 , China
| | - Liucan Wang
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering , Chongqing University , No. 174 Shazheng Road , Chongqing 400044 , China
| | - Haidi Guan
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering , Chongqing University , No. 174 Shazheng Road , Chongqing 400044 , China
| | - Jia Tang
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering , Chongqing University , No. 174 Shazheng Road , Chongqing 400044 , China
| | - Dong Mo
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering , Chongqing University , No. 174 Shazheng Road , Chongqing 400044 , China
| | - Jixi Zhang
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering , Chongqing University , No. 174 Shazheng Road , Chongqing 400044 , China
| |
Collapse
|
12
|
Sun K, Ding T, Xing Y, Mo D, Zhang J, Rosenholm JM. Hybrid mesoporous nanorods with deeply grooved lateral faces toward cytosolic drug delivery. Biomater Sci 2019; 7:5301-5311. [DOI: 10.1039/c9bm01251f] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Hybrid mesoporous nanorods with six twisted sharp edges can induce effective penetration of intracellular barriers and cytosolic delivery of membrane-impermeable drugs through curvature effects.
Collapse
Affiliation(s)
- Kaiyao Sun
- Key Laboratory of Biorheological Science and Technology
- Ministry of Education
- College of Bioengineering
- Chongqing University
- Chongqing 400044
| | - Tao Ding
- Key Laboratory of Biorheological Science and Technology
- Ministry of Education
- College of Bioengineering
- Chongqing University
- Chongqing 400044
| | - Yuxin Xing
- Key Laboratory of Biorheological Science and Technology
- Ministry of Education
- College of Bioengineering
- Chongqing University
- Chongqing 400044
| | - Dong Mo
- Key Laboratory of Biorheological Science and Technology
- Ministry of Education
- College of Bioengineering
- Chongqing University
- Chongqing 400044
| | - Jixi Zhang
- Key Laboratory of Biorheological Science and Technology
- Ministry of Education
- College of Bioengineering
- Chongqing University
- Chongqing 400044
| | - Jessica M. Rosenholm
- Pharmaceutical Sciences Laboratory
- Faculty of Science and Engineering
- Åbo Akademi University
- Turku 20520
- Finland
| |
Collapse
|
13
|
Bae JP, Lage MJ, Mo D, Nelson DR, Hoogwerf BJ. Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009-2011. J Diabetes Complications 2016; 30:212-20. [PMID: 26689451 DOI: 10.1016/j.jdiacomp.2015.11.016] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Revised: 11/13/2015] [Accepted: 11/15/2015] [Indexed: 12/13/2022]
Abstract
AIMS Examine the association between obesity and glycemic control among patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM). METHODS Data from US physician electronic health records (Humedica®) from 2009-2011 were utilized. Patients were defined as having above-target glycemic control if they had an HbA1c ≥7% at any time during the study period. Multinomial logistic regressions were conducted separately for T1DM and T2DM patients, and examined associations between BMI categories and probability of having above-target glycemic control (≥7% and <8%, ≥8% and <9%, or ≥9%) while controlling for patient demographics, general health, comorbid conditions, and antihyperglycemic medication use. RESULTS There were 14,028 T1DM and 248,567 T2DM patients; 47.8% of T1DM and 63.4% of T2DM were obese (BMI ≥30kg/m(2)). For T1DM, being overweight (BMI 25-<30), obese class I (30-<35), II (35-<40), or III (≥40) was associated with a significantly higher probability of having HbA1c≥8% and <9% or ≥9%, while being overweight was associated with a significantly higher probability of having HbA1c ≥7% and <8% compared to normal BMI (BMI≥18.5 and<25). For T2DM patients, being overweight, obese class I, II, or III was associated with a significantly higher probability of having HbA1c ≥7% and <8%, ≥8% and <9%, or ≥9%. CONCLUSIONS For both T1DM and T2DM patients, there were positive and statistically significant associations between being overweight or obese and having suboptimal glycemic control. These findings quantify the associations between obesity and glycemic control, and highlight the potential importance of individual characteristics on glycemic control.
Collapse
Affiliation(s)
- J P Bae
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.
| | - M J Lage
- Managing Member, HealthMetrics Outcomes Research, 27576 River Reach Drive, Bonita Springs FL 34134.
| | - D Mo
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.
| | - D R Nelson
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.
| | - B J Hoogwerf
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.
| |
Collapse
|
14
|
Mo D, Liu L, Chen Y, Yang J, Li J, Wood R, Colclough H, Babineaux SM. Updating Characteristics of Type 2 Diabetes Mellitus Patients in China: Surveys in year 2008 and 2011-12. Value Health 2014; 17:A756. [PMID: 27202754 DOI: 10.1016/j.jval.2014.08.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- D Mo
- Eli Lilly and Company, Indianapolis, IN, USA
| | - L Liu
- Eli Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China
| | - Y Chen
- Eli Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai, China
| | - J Yang
- Eli Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai, China
| | - J Li
- Eli Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai, China
| | - R Wood
- Adelphi Real World, Bollington, UK
| | | | | |
Collapse
|
15
|
Dang Y, Wu B, Sun Y, Mo D, Wang X, Zhang J, Fang J. Quantitative assessment of external carotid artery territory supply with modified vessel-encoded arterial spin-labeling. AJNR Am J Neuroradiol 2012; 33:1380-6. [PMID: 22345497 DOI: 10.3174/ajnr.a2978] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE In patients with carotid stenosis or occlusion, cerebral blood could be supplied through collateral pathways to improve regional blood flow and protect against ischemic events. The contribution of collaterals from the ICA can be assessed by depiction of vascular perfusion territories with ASL. However, so far there is no method available to evaluate the collateral perfusion territory from the ECA in MR imaging. In this study, we present a new labeling scheme based on VE-ASL to quantitatively assess the perfusion territory of the ECA. MATERIALS AND METHODS A new labeling approach with a Hadamard encoding scheme was developed to label major arteries, especially the ECA. Twelve healthy subjects with normal cerebrovascular anatomy were examined to demonstrate their perfusion territories. Eight patients with carotid artery stenosis or occlusion were assessed before and after surgery to show changes of their collateral blood supply. RESULTS The proposed method enables assessment of the perfusion territories of the ECA. Good agreement was found between the vascular territories and normal cerebrovascular anatomy in healthy subjects. For the patients with carotid stenosis or occlusion, our noninvasive results provided information on collateral flow comparable with that from DSA. Their collateral flows from the ECA, moreover, could be quantitatively estimated pre- and postoperatively. CONCLUSIONS The modified approach has been validated by the consistency of collateral perfusion territories with cerebrovascular anatomy, and quantitative assessment of collaterals proved useful for assisting in evaluating therapeutic interventions.
Collapse
Affiliation(s)
- Y Dang
- Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
| | | | | | | | | | | | | |
Collapse
|
16
|
Mo D, Huang J, Jia X, Luan H, Rozelle S, Swinnen J. Checking into China's cow hotels: Have policies following the milk scandal changed the structure of the dairy sector? J Dairy Sci 2012; 95:2282-98. [DOI: 10.3168/jds.2011-4720] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2011] [Accepted: 12/31/2011] [Indexed: 11/19/2022]
|
17
|
Kloner R, Sadovsky R, Johnson E, Mo D, Ahuja S. Efficacy of Tadalafil in the Treatment of Erectile Dysfunction in Hypertensive Men on Concomitant Thiazide Diuretic Therapy. J Urol 2006. [DOI: 10.1016/s0022-5347(05)00873-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- R.A. Kloner
- Division of Cardiovascular Medicine, Heart Institute, Good Samaritan Hospital, Keck School of Medicine at University of Southern California, Los Angeles, California
| | - R. Sadovsky
- Division of Cardiovascular Medicine, Heart Institute, Good Samaritan Hospital, Keck School of Medicine at University of Southern California, Los Angeles, California
| | - E.G. Johnson
- Division of Cardiovascular Medicine, Heart Institute, Good Samaritan Hospital, Keck School of Medicine at University of Southern California, Los Angeles, California
| | - D. Mo
- Division of Cardiovascular Medicine, Heart Institute, Good Samaritan Hospital, Keck School of Medicine at University of Southern California, Los Angeles, California
| | - S. Ahuja
- Division of Cardiovascular Medicine, Heart Institute, Good Samaritan Hospital, Keck School of Medicine at University of Southern California, Los Angeles, California
| |
Collapse
|
18
|
Rodríguez Vela L, Lledó García E, Rajmil O, Mo D, Cassinello A, Casariego J. Preferencia de Tadalafilo vs Sildenafilo en pacientes españoles con disfunción eréctil: resultados procedentes de un estudio multicéntrico internacional. Actas Urol Esp 2006; 30:67-79. [PMID: 16703733 DOI: 10.1016/s0210-4806(06)73399-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
OBJECTIVE To compare patient preference for sildenafil citrate (sildenafil) vs. tadalafil and for their respective dosing instructions in a cohort of Spanish patients with erectile dysfunction (ED). MATERIAL AND METHODS Sixty four Spanish patients from a multicenter, two period, cross-over, double-blind study (265 patients enrolled in total) were randomized to receive on-demand sildenafil 50 mg or tadalafil 20 mg for 12 weeks and afterwards were crossed over to the alternate regimen for another 12 weeks to assess drug preference in an extension period of the study. Similarly, to evaluate preference for their respective dosing instructions, 30 patients were randomized to one of the 2 arms treated with tadalafil: one with sildenafil (S) dosing instructions and the other with tadalafil (T) dosing instructions. RESULTS Seventy percent of 56 patients completing the study chose to receive tadalafil treatment versus sildenafil treatment (30%) in the extension period (p<0.01). Correspondingly, 73% of 13 evaluating each drug dosing instructions preferred T dosing instructions (p>0.05). Preference did not vary with age, concomitant diseases and previous use of sildenafil. CONCLUSIONS In this study, 7 out of 10 patients preferred tadalafil and its dosing instructions to sildenafil, for the treatment of their ED.
Collapse
|
19
|
Rodríguez Vela L, Lledó García E, Rajmil O, Mo D, Cassinello A, Casariego J. Preferencia de Tadalafilo vs Sildenafilo en pacientes españoles con disfunción eréctil: resultados procedentes de un estudio multicéntrico internacional. Actas Urol Esp 2006. [DOI: 10.4321/s0210-48062006000100011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
20
|
Kloner RA, Sadovsky R, Johnson EG, Mo D, Ahuja S. Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int J Impot Res 2005; 17:450-4. [PMID: 16015377 DOI: 10.1038/sj.ijir.3901360] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Many men with erectile dysfunction (ED) have hypertension as a comorbid condition. Recent guidelines recommend thiazide diuretics as first-line therapy for hypertension. We analyzed data from 14 randomized, double-blind, placebo-controlled trials (N=2501) to evaluate the efficacy of tadalafil 20 mg for the treatment of ED in men on thiazides. Of the 2501 patients, 163 were on concomitant thiazides (116 tadalafil/47 placebo) and 159 (98%) were reported to have hypertension. The primary efficacy measures were mean change from baseline in the international index of erectile function (IIEF) erectile function (EF) domain and the proportion of 'yes' responses to sexual encounter profile (SEP) Questions 2 and 3. The tadalafil group showed a significantly (P<0.001) greater mean baseline to endpoint improvement on all efficacy outcome measures compared to placebo-treated patients regardless of concomitant thiazide use. More importantly, the responses to tadalafil were similar regardless of concomitant thiazide use. Additionally, responses to tadalafil were comparable between thiazide and nonthiazide users regardless of baseline ED severity (P>0.05).
Collapse
Affiliation(s)
- R A Kloner
- Division of Cardiovascular Medicine, Heart Institute, Good Samaritan Hospital, Keck School of Medicine at University of Southern California, Los Angeles, CA 90017, USA.
| | | | | | | | | |
Collapse
|
21
|
Mo D. Injury mortality risk assessment and targeting the subpopulations for prevention in the Northwest Territories, Canada. Int J Circumpolar Health 2001; 60:391-9. [PMID: 11590879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Prevention of injury mortality is a top priority for public health in the Northwest Territories, Canada. However, the frequency of injury mortality may not be evenly distributed in subgroups. Assessment of population relative risk of injury mortality can assist in better targeting of prevention programs. METHODS A population-based case-control study consisting of 197 cases was used to quantify the relative risks of injury mortality for variables age, sex, ethnicity, geographic location and remoteness. RESULTS A multivariate logistic model showed that the odds ratios were 2.90 (95% CI 2.09-4.03) for males, 3.39 (95% CI 2.55-4.52) for age group 15-64 years, 11.50 (95% CI 6.47-20.42) for age group over 64 years, 1.51 (95% CI 1.13-2.02) for people in remote communities, and 2.04 (95% CI 1.50-2.79) for people above 66 degrees latitude. Aboriginal people of Dene and Inuit presented increased risks in the stratified analysis by community remoteness and latitude. CONCLUSIONS Males, over age 14, living in remote communities, living in the far north, and being aboriginal were at higher risk of injury mortality. Based on the relative risks of injury mortality and the population size in each subpopulation, injury prevention investments should be extended to remote communities.
Collapse
Affiliation(s)
- D Mo
- Department of Epidemiology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
| |
Collapse
|
22
|
Mo D, Ni Y, Huang Z. [Study on the elements in cosmetics by microwave digestion-iCP-AES I. The determination of Pb, As, Cr, Cd, Sr, Bi and Se in solid state cosmetics]. Guang Pu Xue Yu Guang Pu Fen Xi 1999; 19:598-600. [PMID: 15818968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
A safe and effective method for the microwave digestion of solid state cosmetic samples is described. The overall digestion conditions, including pressure, power, acids and time of digestion were evaluated by analysing Pb, As, Cr, Cd, Sr, Bi and Se of routine samples with ICP-AES. This method was applied to the determination of certified materials with good agreement.
Collapse
Affiliation(s)
- D Mo
- Chengdu Sanitation and Antiepidemic Station, 610021 Chengdu
| | | | | |
Collapse
|
23
|
Li S, Liu C, Klimov A, Subbarao K, Perdue ML, Mo D, Ji Y, Woods L, Hietala S, Bryant M. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis 1999; 179:1132-8. [PMID: 10191214 DOI: 10.1086/314713] [Citation(s) in RCA: 102] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Recombinant reassortment technology was used to prepare H5N1 influenza vaccine strains containing a modified hemagglutinin (HA) gene and neuraminidase gene from the A/Hong Kong/156/97 and A/Hong Kong/483/97 isolates and the internal genes from the attenuated cold-adapted A/Ann Arbor/6/60 influenza virus strain. The HA cleavage site (HA1/HA2) of each H5N1 isolate was modified to resemble that of "low-pathogenic" avian strains. Five of 6 basic amino acids at the cleavage site were deleted, and a threonine was added upstream of the remaining arginine. The H5 HA cleavage site modification resulted in the expected trypsin-dependent phenotype without altering the antigenic character of the H5 HA molecule. The temperature-sensitive and cold-adapted phenotype of the attenuated parent virus was maintained in the recombinant strains, and they grew to 108.5-9.4 EID50/mL in eggs. Both H5N1 vaccine virus strains were safe and immunogenic in ferrets and protected chickens against wild-type H5N1 virus challenge.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Antibodies, Viral/biosynthesis
- Antigens, Viral/immunology
- Chickens
- Drug Design
- Ferrets
- Genes, Viral
- Hemagglutinin Glycoproteins, Influenza Virus/genetics
- Hemagglutinin Glycoproteins, Influenza Virus/immunology
- Humans
- Influenza A Virus, H5N1 Subtype
- Influenza A virus/genetics
- Influenza A virus/immunology
- Influenza A virus/physiology
- Influenza Vaccines/immunology
- Influenza, Human/immunology
- Influenza, Human/prevention & control
- Influenza, Human/virology
- Molecular Sequence Data
- Neuraminidase/genetics
- Neuraminidase/immunology
- Vaccines, Attenuated/immunology
- Vaccines, Synthetic/immunology
- Viral Plaque Assay
Collapse
Affiliation(s)
- S Li
- Aviron, Mountain View, California Veterinary Diagnostic Laboratory CA System, Davis, CA, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Fang K, Xu J, Mai K, Wang X, Li Q, Mo D. [Spectroscopic ellipsometry characteristics and the optical properties of liquid crystalline copolyesters]. Guang Pu Xue Yu Guang Pu Fen Xi 1998; 18:399-403. [PMID: 15825328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
The optical properties of two thermotropic liquid crystalline copolyesters were characterized by spectroscopic ellipsometry and UV-visible spectroscopy. The differences in the refractive index variation and chromatic dispersion have been revealed and discussed in terms of differences in the vibrating transition of excited electrons and the molecular structures of the polymers.
Collapse
Affiliation(s)
- K Fang
- Materials Science Institute of Zhongshan University, Laboratory of polymeric Composite and Functional Material, State Education Commission of China, 510275 Guangzhou
| | | | | | | | | | | |
Collapse
|
25
|
Chen YC, Zheng XY, Lai TS, Xu XS, Mo D, Lin WZ. Resonators for self-mode-locking Ti:sapphire lasers without apertures. Opt Lett 1996; 21:1469-1471. [PMID: 19881694 DOI: 10.1364/ol.21.001469] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
It is advantageous to achieve stable self-mode locking without hard apertures by designing resonators to minimize cavity-dispersion noncoaxiality in Brewster-cut gain media. The cavity-loss modulation introduced by Kerr effects is then optimized.
Collapse
|
26
|
Jian Z, Guisun Z, Yongji W, Mo D, Fulin Z. Activation analysis study on subcellular distribution of trace elements in human brain tumor. J Radioanal Nucl Chem 1992. [DOI: 10.1007/bf02169576] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
He XF, Jiang RR, Mo D. Optical analyses of radiation effects in ion-implanted Si: Fractional-derivative-spectrum methods. Phys Rev B Condens Matter 1990; 41:5799-5805. [PMID: 9994464 DOI: 10.1103/physrevb.41.5799] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
28
|
Huang X, Mo D, Yeah K, Winefordner J. Effect of radiofrequency power on laser induced fluorescence and emission spectrometry with an extended-sleeve inductively-coupled plasma torch. Anal Chim Acta 1986. [DOI: 10.1016/s0003-2670(00)86496-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
29
|
Chin KK, Pan SH, Mo D, Mahowald P, Newman N, Lindau I, Spicer WE. Electronic structure and Schottky-barrier formation of Ag on n-type GaAs(110). Phys Rev B Condens Matter 1985; 32:918-923. [PMID: 9937100 DOI: 10.1103/physrevb.32.918] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/11/2023]
|